Mouse mammary hyperplasias and neoplasias exhibit different patterns of cyclins D1 and D2 binding to cdk4

T K Said1, L Luo, D Medina

  • 1Baylor College of Medicine, Department of Cell Biology, Houston, TX 77030, USA.

Carcinogenesis
|October 1, 1995
PubMed

Insights

Cyclin D2 plays a unique role in early mammary tumor development, potentially promoting differentiation. Cyclin D1 then takes over, driving proliferation and tumor growth.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Deregulated expression of G1 cyclins D1 and D2 is observed in various cancers.
  • Understanding the specific roles of cyclin D1 and D2 in tumorigenesis is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the differential expression and function of cyclin D1 and D2 during mouse mammary tumorigenesis.
  • To analyze the association of cyclin D1 and D2 with cyclin-dependent kinases (cdk4 and cdk2) at different stages of tumor development.

Main Methods:

  • Analysis of cyclin D1 and D2 protein and mRNA levels in normal mammary glands, hyperplastic outgrowths, and tumors from mouse models.
  • Assessment of cyclin D1 and D2 binding to cdk4 and cdk2.
  • Measurement of cdk4 kinase activity.

Main Results:

  • Cyclin D1 protein levels, its binding to cdk4/cdk2, and cdk4 kinase activity increased with tumorigenesis.
  • Cyclin D2 binding to cdk4 was high in hyperplasias but decreased in tumors, where cyclin D1 predominated.
  • Despite decreased binding, cyclin D2 protein levels significantly increased in hyperplasias and tumors, while its mRNA levels were highest in normal tissue.

Conclusions:

  • Cyclin D2 appears to have a distinct function in early mammary tumor development, potentially mediating differentiation.
  • The shift from cyclin D2 to cyclin D1 binding with cdk4 may represent a critical switch from differentiation to proliferation, leading to neoplasia.
  • Cyclin D2-cdk4 interaction might act as a negative regulatory mechanism in early stages, preventing uncontrolled proliferation until overridden by cyclin D1.

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...